Adenosine A2A receptor and dopamine D3 receptor interactions: Evidence of functional A2A/D3 heteromeric complexes

Molecular Pharmacology

Volumn 67, Issue 2, 2005, Pages 400-407

  Torvinen, Maria ^a   Marcellino, Daniel ^b   Canals, Meritxell ^a   Agnati, Luigi F ^c   Lluis, Carmen ^b   Franco, Rafael ^b   Fuxe, Kjell ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; CYCLIC AMP; DOPAMINE; DOPAMINE 3 RECEPTOR; FORSKOLIN; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; TRITIUM; YELLOW FLUORESCENT PROTEIN; ADENOSINE; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, HUMAN; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR AFFINITY; CHEMISTRY; COMPARATIVE STUDY; DRUG POTENTIATION; HELA CELL; METABOLISM; METHODOLOGY; PHYSIOLOGY; RADIOASSAY;

ADENOSINE; DOPAMINE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HELA CELLS; HUMANS; MICROSCOPY, CONFOCAL; PHENETHYLAMINES; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 13444271067     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.003376     Document Type: Article

References (37)

1. Agnati LF, Ferre S, Leo G, Lluis C, Canela EI, Franco R, and Fuxe K (2004) On the molecular basis of the receptor mosaic hypothesis of the engram. Cell Mol Neurobiol 24:501-516.
2. Agnati LF, Ferre S, Lluis C, Franco R, and Fuxe K (2003) Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 55:509-550.
3. Andersen MB, Fuxe K, Werge T, and Gerlach J (2002) The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav Pharmacol 13:639-644.
4. 125I]- iodosulpride. Synapse 19:1-13.
5. Canals M, Burgueno J, Marcellino D, Cabello N, Canela EI, Mallol J, Agnati L, Ferre S, Bouvier M, Fuxe K, et al. (2004) Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem 88:726-734.
6. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, et al. (2003) Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278:46741-46749.
7. Cussac D, Newman-Tancredi A, Pasteau V, and Millan MJ (1999) Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase c-dependent mechanism. Mol Pharmacol 56:1025-1030.
8. Dasgupta S, Ferre S, Kull B, Hedlund PB, Finnman UB, Ahlberg S, Arenas E, Fredholm BB, and Fuxe K (1996) Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. Eur J Pharmacol 316:325-331.
9. Diaz-Cabiale Z, Hurd Y, Guidolin D, Finnman UB, Zoli M, Agnati LF, Vanderhaeghen JJ, Fuxe K, and Ferre S (2001) Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport 12:1831-1834.
10. Ferre S, Torvinen M, Antoniou K, Irenius E, Civelli O, Arenas E, Fredholm BB, and Fuxe K (1998) Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J Biol Chem 273:4718-4724.
11. Ferre S, von Euler G, Johansson B, Fredholm BB, and Fuxe K (1991) Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88:7238-7241.
12. Franco R, Canals M, Marcellino D, Ferre S, Agnati L, Mallol J, Casado V, Ciruela F, Fuxe K, Lluis C, et al. (2003) Regulation of heptaspanning-membrane- receptor function by dimerization and clustering. Trends Biochem Sci 28:238-243.
13. Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, et al. (2003) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61:19S-23S.
14. Fuxe K, Ferre S, Zoli M, and Agnati LF (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res Brain Res Rev 26:258-273.
15. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, et al. (2000) Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97:8606-8611.
16. Giros B, Martres MP, Sokoloff P, and Schwartz JC (1990) Gene cloning of human dopaminergic D3 receptor and identification of its chromosome. C R Acad Sci III Sci Vie 311:501-508.
17. 3H-dopamine in neostriatal membrane preparations: inhibitory effects of sodium ascorbate. Life Sci 32:2183-2191.
18. Hillefors M, Hedlund PB, and von Euler G (1999a) Effects of adenosine A(2A) receptor stimulation in vivo on dopamine D3 receptor agonist binding in the rat brain. Biochem Pharmacol 58:1961-1964.
19. 3H]PD 128907 in the caudate-putamen of the adult rat. Brain Res 20:126-131.
20. Hillion JA, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, et al. (2002) Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277:18091-18097.
21. Jordan M, Schallhorn A, and Wurm F (1996) Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24:596-601.
22. Kamiya T, Saitoh O, Yoshioka K, and Nakata H (2003) Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 306:544-549.
23. Klotz KN (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol 362:382-391.
24. Kull B, Ferre S, Arslan G, Svenningsson P, Fuxe K, Owman C, and Fredholm BB (1999) Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem Pharmacol 58:1035-1045.
25. Lillrank SM, Lipska BK, Weinberger DR, Fredholm BB, Fuxe K, and Ferre S (1999) Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochem Int 34:235-244.
26. Maggio R, Scarselli M, Novi F, Millan MJ, and Corsini GU (2003) Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 87:631-641.
27. Manders EMM, Verbeek EJ, and Aten JA (1993) Measurement of co-localization of objects in dual-colour confocal images. J Microsc 169:175-182.
28. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
29. Nimchinsky EA, Hof PR, Janssen WG, Morrison JH, and Schmauss C (1997) Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J Biol Chem 272:29229-29237.
30. Rimondini R, Ferre S, Ogren SO, and Fuxe K (1997) Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17:82-91.
31. Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, Griffon N, Corsini GU, Sokoloff P, Levenson R, et al. (2001) D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276:30308-30314.
32. Schwartz JC (2003) The dopamine D3 receptor and its ligands: therapeutic implications. Eur Neuropsychopharmacol 13:S166-S167.
33. Schwartz J-C, Diaz J, Pilon C, and Sokoloff P (2000) Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 31:277-287.
34. Tanganelli S, Sandager Nielsen K, Ferraro L, Antonelli T, Kehr J, Franco R, Ferré S, Agnati LF, Fuxe K, et al. (2004) Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's disease. Parkinsonism Relat Disord 10:273-280.
35. Torvinen M, Kozell LB, Neve KA, Agnati LF, and Fuxe K (2004) Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor. J Mol Neurosci 24:273-280.
36. Torvinen M, Torri C, Tombesi A, Marcellino D, Watson S, Lluis C, Franco R, Fuxe K, and Agnati L (2005) Trafficking of adenosine A2A and dopamine D2 receptors. J Mol Neurosci, in press.
37. Zimmermann T, Rietdorf J, Girod A, Georget V, and Pepperkok R (2002) Spectral imaging and linear un-mixing enables improved FRET efficiency with a novel GFP2-YFP FRET pair. FEBS Lett 531:245-249.